Stimcell Energetics (STME) Net Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | Stimcell Energetics | - | - | - | -50.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -50.02% |
| Nov 30, 2025 | 65.76% |
| Aug 31, 2025 | 17.79% |
| May 31, 2025 | 47.09% |
| Feb 28, 2025 | -58.57% |
| Nov 30, 2024 | 36.04% |
| Aug 31, 2024 | -36.39% |
| May 31, 2024 | -82.01% |
| Feb 29, 2024 | 224.22% |
| Nov 30, 2023 | 28.86% |
| Aug 31, 2023 | -36.33% |
| May 31, 2023 | 49.50% |
| Feb 28, 2023 | 59.43% |
| Nov 30, 2022 | 28.32% |
| Aug 31, 2022 | -27.03% |
| May 31, 2022 | 54.49% |
| Feb 28, 2022 | -27.29% |
| Nov 30, 2021 | -91.29% |
| Aug 31, 2021 | 100.23% |
| May 31, 2021 | 26.67% |
| Feb 28, 2021 | 26.40% |
| Nov 30, 2020 | 23.41% |
| Aug 31, 2020 | -33.58% |
| May 31, 2020 | -46.35% |
| Feb 29, 2020 | -13.41% |
| Nov 30, 2019 | -43.80% |
| Aug 31, 2019 | 203.66% |
| May 31, 2019 | -84.81% |
| May 31, 2016 | 128.74% |